NCT07062055View on ClinicalTrials.gov

BRAVE Study: QL1706 + Bevacizumab + SBRT for BCLC-C HCC With PVTT or Oligometastases

PHASE2RecruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

July 25, 2025

Primary Completion Date

July 25, 2028

Study Completion Date

July 25, 2029

Conditions
Hepatocellular CarcinomaPortal Vein Tumor ThrombusOligometastasesRadiotherapyImmunotherapyAnti-VEGF Therapy
Interventions
DRUG

Anti-VEGF

Drug: Bevacizumab (15 mg/kg, IV, every 3 weeks)

DRUG

Immunotherapy

QL1706 (7.5 mg/kg, IV, every 3 weeks, administered sequentially after bevacizumab)

RADIATION

Local Therapy

Stereotactic Body Radiotherapy (SBRT), total dose of 25-50 Gy in 5 fractions over 1-2 weeks, targeting intrahepatic tumors, portal vein tumor, and/or limited extrahepatic oligometastatic lesions

Trial Locations (1)

Unknown

RECRUITING

Shandong Cancer Hospital and Institute, Jinan

All Listed Sponsors
lead

Shandong Cancer Hospital and Institute

OTHER

NCT07062055 - BRAVE Study: QL1706 + Bevacizumab + SBRT for BCLC-C HCC With PVTT or Oligometastases | Biotech Hunter | Biotech Hunter